Literature DB >> 3401060

Lethal "thin" malignant melanoma. Identifying patients at risk.

C L Slingluff1, R T Vollmer, D S Reintgen, H F Seigler.   

Abstract

Thin melanomas can metastasize and be lethal. The purpose of this review was to identify negative risk factors in patients with melanomas less than 0.76 mm thick. Six hundred and eighty-one (681) such patients are reviewed in this study. Of those referred without metastatic disease (583 patients), metastases developed in 4.8% after a mean followup of 3.6 years. Of those referred with metastatic disease (98 patients), mortality was 35% after a mean followup of 5.9 years. Male patients (p less than 0.04) and patients with axial primaries (p less than 0.05) were at an increased risk of metastasis. Severe histologic regression was present in 40% of the primary lesions that metastasized and in only 17% of similar lesions that did not (p less than 0.001). Increased age was associated with increased local skin metastases, but not with increased nodal or distant metastases. A prognostic model was designed, using two clinical risk factors (axial primary site and male sex) and two histologic risk factors (Clark's Level IV and severe histologic regression). The prognostic model identified a low-risk population--women with extremity primaries--with an actuarial risk of metastasis at 10 years that was less than 3%. Patients with either (1) both clinical risk factors or (2) one clinical risk factor and one histologic risk factor were identified as high-risk patients. Their actuarial risk of metastasis was 11% at 5 years and 22% at 10 years (p = 0.0084). Identifying high-risk and low-risk patients with thin melanomas may improve guidelines for the application of adjuvant therapies to this population.

Entities:  

Mesh:

Year:  1988        PMID: 3401060      PMCID: PMC1493625          DOI: 10.1097/00000658-198808000-00004

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis.

Authors:  A C ALLEN; S SPITZ
Journal:  Cancer       Date:  1953-01       Impact factor: 6.860

2.  In search of thin lethal melanomas.

Authors:  A Breslow
Journal:  Surg Gynecol Obstet       Date:  1976-11

3.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

4.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

5.  Specific active immunotherapy for melanoma.

Authors:  H F Seigler; E Cox; F Mutzner; L Shepherd; E Nicholson; W W Shingleton
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

6.  Regional lymph node metastases and the level of invasion of primary melanoma.

Authors:  E C Holmes; W Clark; D L Morton; F R Eilber; A J Bochow
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

7.  Evaluation of prognosis in Stage I cutaneous melanoma.

Authors:  A Breslow; S D Macht
Journal:  Plast Reconstr Surg       Date:  1978-03       Impact factor: 4.730

8.  On the prognostic importance of white depressed areas in the primary lesion of superficial spreading melanoma.

Authors:  D I McLean; R A Lew; A J Sober; M C Mihm; T B Fitzpatrick
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

9.  Tumour thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I).

Authors:  G W Milton; H M Shaw; G A Farago; W H McCarthy
Journal:  Br J Surg       Date:  1980-08       Impact factor: 6.939

10.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

View more
  19 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

2.  Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain.

Authors:  Sumeet Thareja; Jonathan S Zager; Divya Sadhwani; Shalini Thareja; Ren Chen; Suroosh Marzban; Drazen M Jukic; Lewis F Glass; Jane Messina
Journal:  Am J Dermatopathol       Date:  2014-01       Impact factor: 1.533

Review 3.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

4.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

5.  Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.

Authors:  Richard L White; Gregory D Ayers; Virginia H Stell; Shouluan Ding; Jeffrey E Gershenwald; Jonathan C Salo; Barbara A Pockaj; Richard Essner; Mark Faries; Kim James Charney; Eli Avisar; Axel Hauschild; Friederike Egberts; Bruce J Averbook; Carlos A Garberoglio; John T Vetto; Merrick I Ross; David Chu; Vijay Trisal; Harald Hoekstra; Eric Whitman; Harold J Wanebo; Daniel Debonis; Michael Vezeridis; Aaron Chevinsky; Mohammed Kashani-Sabet; Yu Shyr; Lynne Berry; Zhiguo Zhao; Seng-Jaw Soong; Stanley P L Leong
Journal:  Ann Surg Oncol       Date:  2011-06-07       Impact factor: 5.344

6.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

7.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

8.  Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-(99m)Tc-nanocolloid hybrid tracer versus (99m)Tc-nanocolloid.

Authors:  Ingo Stoffels; Julia Leyh; Thorsten Pöppel; Dirk Schadendorf; Joachim Klode
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-31       Impact factor: 9.236

9.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

Review 10.  Melanoma biomarkers: current status and vision for the future.

Authors:  Allison R Larson; Eliz Konat; Rhoda M Alani
Journal:  Nat Clin Pract Oncol       Date:  2008-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.